Shionogi enrols first patients in Esprit trial for Pompe disease

The trial will examine the efficacy, safety, and pharmacodynamics of S-606001 SRT used with ERT in confirmed LOPD adults.
PharmiWeb

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

S-606001 has the potential to become the first oral substrate reduction therapy for Pompe diseaseOSAKA, Japan--(BUSINESS WIRE ...

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines in areas of high unmet need in rare muscle diseases, ...
Hosted on MSN

The Carb Secret: How Glycogen Supercharges Muscle Growth, Strength & Recovery

When people think of "muscle building," their first thought is protein. And while protein is the raw material for muscle tissue, it is not the only thing. If you're ignoring carbs, you are probably ...
Medical Xpress

'Carb-loading' is a myth. But how much carbohydrate do athletes really need?

For many years, sports nutrition was rooted in a simple metaphor: The body is an engine, glycogen (the body's quick-release carbohydrate reserve) is its fuel, and fatigue occurs when the tank runs low ...